Science

Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors

Drew Moghanaki/X

Feb 28, 2025, 14:43

Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors

Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared an article by Andres Huertas, et al. on X:

“A trio of radiation oncologists from France, the United States, and Australia asks why there is a desire to deliver SBRT to ultra-central tumors.

Especially when a 3-week hypofractionation (60/15) course seems to be just fine.”

Comment on Wu et al’s article on toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer.

Authors: Andres Huertas, et al.

Drew Moghanaki: Why there is a desire to deliver SBRT to ultra-central tumors

Andres Huertas cancer Drew Moghanaki fight against cancer Global fight against cancer non small cell lung cancer NSCLC OncoDaily Oncology radiotherapy RadOnc SBRT UCLA ultra-central tumors

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more